bYoRNA

Executive Summary

bYoRNA is a French biotechnology company founded in 2021 that has developed a proprietary RNA production platform based on eukaryotic cell biofactories. This innovative approach enables the production of high-quality messenger RNA (mRNA) at a fraction of current costs, addressing a key bottleneck in the RNA therapeutics industry. The company's technology aims to democratize access to mRNA-based therapies, with initial applications in oncology, infectious diseases, and rare diseases. By leveraging eukaryotic cells, bYoRNA's platform can produce complex RNA molecules that are more stable and effective than those generated by traditional in vitro transcription methods, potentially unlocking new therapeutic possibilities. The RNA therapeutics market is rapidly expanding, driven by the success of mRNA vaccines and the growing pipeline of RNA-based drugs. bYoRNA's cost-efficient manufacturing platform positions it as a potential enabler for a wide range of developers, especially in resource-limited settings. However, as an early-stage private company with no disclosed funding or clinical-stage candidates, bYoRNA faces significant development and commercialization risks. The company's success will depend on securing partnerships, raising capital, and validating its platform through preclinical and clinical studies. If successful, bYoRNA could become a critical supplier in the RNA therapeutics supply chain, but investors should closely monitor progress in platform validation and strategic collaborations.

Upcoming Catalysts (preview)

• TBDPartnership with major pharmaceutical company for mRNA manufacturing30% success
• TBDSeries A funding round to advance platform development50% success
• TBDPublication of preclinical proof-of-concept data for oncology mRNA therapy60% success